The test is non-invasive (no needles, no pinching) and takes only a few minutes, making it easy to repeat over time
Moreover, clinical studies have begun to explore the therapeutic potential of semaglutide in patients with UC, with preliminary findings suggesting promising outcomes in terms of disease activity reduction, mucosal healing, and improvement in patient-reported outcomes
Similarly, in the overweight or obese group, 20 NAION events occurred in the semaglutide group compared to 3 events in the non-GLP-1 RA group
References Srensen TIA, Martinez AR, Jrgensen TSH
October 14th, 2025: Plaintiffs Seek Separate MDL for Vision Loss Claims Linked to Ozempic, Wegovy, and Mounjaro Plaintiffs in the GLP-1 drug litigation are urging the U.S
This matters because visceral adiposity drives metabolic disease far more potently than subcutaneous fat